Azenta (AZTA) Earnings Date & Reports

Azenta's revenue from continuing operations reached $145 million, a 1% increase year-over-year, driven by growth in Sample Repository Solutions, Product Services, Consumables and Instruments, and a small contribution from the UK Biocentre acquisition. However, organic revenue fell 3%, missing consensus estimates of $148 million, due to softer demand in North America and declines in Core Products like Automated Stores and Sanger Sequencing.

Non-GAAP diluted EPS from continuing operations was -$0.04, versus prior-year $0.01 and analyst expectations of $0.10-$0.14. GAAP diluted EPS was -$3.41, impacted by the $149 million goodwill impairment. Gross margin dipped to 42.8% (adjusted 44.3%), reflecting lower volume absorption, Automated Stores rework costs, and inventory reserves. Adjusted EBITDA margin contracted to 5.4% from 8.6%.

Guidance was lowered: FY2026 reported revenue now $603-$621 million (organic -2% to +1% YoY, versus prior 3%-5% growth); Sample Management low-single-digit growth; Multiomics mid-single-digit decline. Free cash flow expected to improve 10%-15% YoY. The long-range plan timeline shifted to 2029.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis.

Market Reaction and Investor Sentiment

Azenta's shares plunged over 20%-25% in premarket trading on May 6, 2026, following the release, dropping from a prior close near $24.61 to around $19. The sharp decline reflects disappointment over the revenue and EPS misses, significant impairments, and lowered FY2026 guidance amid execution gaps and North American softness. Sentiment turned cautious, with the stock nearing its 52-week low, though some see potential undervaluation.

Forward Outlook and Key Factors to Monitor

Azenta faces near-term headwinds but emphasizes operational improvements. Investors should track progress in the Multiomics transformation, including new leadership and the Azenta Business System for productivity gains. Recurring revenue streams like Sample Repository Solutions and Consumables showed resilience, offering stability amid demand caution.

Updated FY2026 guidance signals moderated growth: organic revenue -2% to +1%, with Sample Management in low-single-digits positive and Multiomics in mid-single-digit decline. Adjusted EBITDA margin expansion is now flat to down 125 basis points (excluding acquisition dilution). Free cash flow improvement of 10%-15% remains a focus, supported by $565 million in liquidity.

Key catalysts include the potential B Medical Systems divestiture (delayed due to buyer financing), UK Biocentre integration, and long-range plan extension to 2029. Monitor North American demand recovery, cost discipline, gross margin trends from volume absorption and inventory management, and geopolitical/macro impacts. Execution on strategic priorities will shape confidence in sustained value creation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations